Clene Inc (CLNN) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Clene Inc   (NASDAQ: CLNN)


Clene Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Clene Inc 's ROA in the second quarter of 2026?
Clene Inc recorded a cumulative net loss of $-40 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -185.64%.

However, within the Healthcare sector 842 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 4412, from total ROA ranking in the first quarter of 2026 at 5012.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 4.14 % -14.41 % -33.24 % -29.33 % -45.14 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -40 -34 -26 -30 -30
Return On Assets (TTM) -185.64 % -159.15 % -119.13 % -125.88 % -111.92 %
CLNN's Total Ranking # 4412 # 5012 # 4457 # 4496 # 4490
Total Assets (TTM) in million 23 22 18 22 22
Seq. Total Assets Change 6.35 % 19.49 % -18.74 % 0.84 % -12.6 %
Seq. Net Income Change - - - - -

CLNN's 5 Years Annual ROA >> Back to CLNN Management Effectiveness >> Compare CLNN ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 399
Sector # 843
Overall # 4419

Return On Assets Statistics
High Average Low
26.46 %
-81.84 %
-185.64 %
(Jun 30 2022)   (Jun 30 2026)



  News about Clene Inc Return on Assets ROA

Clene Inc. Prepares for Pivotal FDA Conference, Charting a Course Toward a Potential ALS Breakthrough,

Clene Inc. Taps into Potential ALS Breakthrough with FDA In-Person Meeting on CNM-Au8 Development
In a significant development for neurodegenerative disease treatment, Clene Inc. (Nasdaq: CLNN), along with its wholly owned subsidiary Clene Nanomedicine Inc. has been granted an in-person meeting with senior leadership at the U.S. Food and Drug Administration (FDA) to discuss its groundbreaking treatment for amyotrophic lateral sclerosis (ALS), CNM-Au8. Scheduled to take place before the end of November 2024, this meeting underscores the company s commitment to advancing its innovative approaches in the fight against ALS and potentially other neurodegenerative diseases.


The Context of Clene s Initiative
Clene Inc. has positioned itself as a late clinical-stage biopharmaceutical company focusing on improving mitochondrial health and protecting neuronal function — crucial factors in combatting ALS and multiple sclerosis (MS). ALS, a progressive disease that devastates nerve cells in the brain and spinal cord, currently has no cure, leaving many patients desperately searching for effective treatment options. Thus, Clene s work to develop CNM-Au8 offers a beacon of hope amid escalating challenges faced by patients and healthcare providers alike.



Financial Statements
Clene Inc 's Assets $ 23 million CLNN's Balance sheet
Clene Inc 's Income $ -13 million Quarterly CLNN's Income Statement
CLNN's Income by Division See CLNN's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change -33.24 % -48.12 % 18.43 % -29.92 % -53.65 %
Total Assets in million 18 27 52 44 63
Y / Y Net Income Change - - - - -
Net Income in million -26 -39 -50 -30 -10
Annual Return On Assets -144.35 % -145.08 % -94.58 % -67.7 % -15.44 %

CLNN's 5 Years Annual ROA >> Back to CLNN Management Effectiveness >> Compare CLNN ROA to its Competitors



More Return On Assets Ratios
CLNN's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CLNN's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CLNN's Competitors
Subscribers only: Roa for Clene Inc 's Suppliers
Subscribers only: Return On Assets for CLNN's Customers

You may also want to know
CLNN's Roi CLNN's Inventory Turnover Ratio CLNN's Growth Rates CLNN's Dividend Comparisons
CLNN's Profitability Ratios CLNN's Asset Turnover Ratio CLNN's Dividend Growth
CLNN's Roe CLNN's Valuation Ratios CLNN's Financial Strength Ratios CLNN's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA

Date modified: 2026-09-26T07:39:49+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.